ChromaDex Initiates First Human Clinical Study for Its New Caffeine Ingredient Technology

19 Apr 2013 --- ChromaDex Corporation, an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced the initiation of the first human clinical study in the U.S. for PURENERGY.

PURENERGY is a patented co-crystal ingredient comprised of caffeine and ChromaDex's pTeroPure pterostilbene that forms a unique crystalline structure having superior benefits as compared to the two individual components alone. Recently, caffeinated energy products have been coming under increased regulatory and political scrutiny regarding the possible risks of consuming high amounts of caffeine. This patented new ingredient technology should allow formulators of caffeinated energy products the opportunity to reduce the total amount of caffeine without affecting the consumers' product experience.

The human study is intended to confirm an earlier animal study which showed PURENERGY had a 6-8 times longer half-life as compared to caffeine alone.1 The results of the animal study suggest that PURENERGY may provide longer sustained energy and alertness with reduced amounts of caffeine and without the "crash" typically experienced when ingesting caffeinated energy products.

The clinical trial is designed to determine the safety, relative bioavailability and pharmacokinetics of PURENERGY as compared to pterostilbene and caffeine alone. The start of this trial in the U.S. follows the recent commercial launch of PURENERGY.

Frank Jaksch , co-founder and CEO of ChromaDex stated, "The study will provide valuable insight about the benefits of PURENERGY and be an important addition to the previously successful animal study. We believe the introduction of PURENERGY is timely given the current regulatory scrutiny of caffeinated energy products."

Given the co-crystal formulation with pTeroPure, PURENERGY also has additional functional health benefits that include cognitive function, antioxidant activity, heart health and weight management support. ChromaDex's patented pTeroPure is a 99 percent pure nature identical pterostilbene with seven patents pending or issued. pTeroPure was named the 2010 North American Most Promising Ingredient of the Year by the independent research company, Frost & Sullivan. PURENERGY and pTeroPure are manufactured exclusively for ChromaDex by Laurus Labs, one of the leaders in API manufacturing.